Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy

Abstract

This invention relates to methods and pharmaceutical compositions for providing hormone replacement therapy in perimenopausal, menopausal, and postmenopausal women through the continuous administration of combinations of conjugated estrogens and trimegestone.

Description

[0001] background technical field [0002] The present invention relates to methods and pharmaceutical compositions for providing hormone replacement therapy to premenopausal, menopausal and postmenopausal women by the continuous administration of a combination of conjugated estrogens and trimegestone. Background technique [0003] Menopause is usually defined as the last menstrual period and is characterized by the cessation of ovarian function, resulting in a substantial decrease in circulating estrogen in the bloodstream. According to recall, menopause is usually defined as after 12 months of amenorrhea. This is usually not a sudden event, but a period of irregular menstrual cycles before the last menstrual period stops. After cessation of menstruation, endogenous estrogen concentrations generally decline rapidly. Circulating levels of plasma estrogen in postmenopausal women fall from 40-250 pg / mL estradiol and 40-170 pg / mL estrone during the ovulation cycle to less tha...

AI Technical Summary

Problems solved by technology

There is currently no acceptable alternative to estrogen therapy for atrophic changes i